METCrusaders· @metcrusaders · X·· 1 天前评分45
正文 · 原文
Promising news about osimertinib + savolitinib for EGFR-mutated NSCLC with MET overexpression or MET amplification #lscm #ESMO26
5 浏览 · 0 赞 · 0 转发 · 0 回复
Simultaneous publication @NEJM of #ESMO26 presentation from Dr. Shun Lu. Osimertinib + savolitinib superior to chemo in EGFR+ NSCLC post osimertinib with MET overexpression and/or amp: 338 randomized / 1746 screened: PFS 7.6 vs 5.4m, HR 0.55, OS HR 0.68 https://www.nejm.org/doi/full/10.1056/NEJMoa2611335在 X 查看被引用的帖子
来源：METCrusaders · x.com